Product Details | |
---|---|
Synonyms | Inhibitory ODN (iODN): Class I |
Product Type | Chemical |
Properties | |
MW | 4,887g/mol |
Sequence |
5’-tcctggcggggaagt-3’ (lower case letters: phosphorothioate linkage: nuclease resistant) |
Reconstitution | For a 100μM stock solution, dissolve total vial content in 2050μl (1mg size) or 205μl (100μg size) sterile endotoxin-free water or PBS. |
Formulation | Lyophilized. Sterile. |
Biological Activity |
Potent sequence of an inhibitory ODN for in vivo use in rodents (50-150μg per injection): prototype class I, may also affect TLR7 and TLR8 signaling. |
Endotoxin Content | <0.002eu g="">0.002eu> |
Declaration | Manufactured by Innaxon. |
Other Product Data |
Contains: 100μg size includes 1.5ml ddWater Endotoxin-free (sterile) (Cat. No.: IAX-900-002-LD15). 1mg and 3 x 1mg sizes each include 10ml ddWater Endotoxin-free (sterile) (Cat. No.: IAX-900-002-L010). |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | +4°C |
Handling Advice |
Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and keep aqueous stock solutions for 1 day at 4°C or store at -20°C (shelf-life 6 months). |
Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
In recent years several groups have studied the sequence requirements, specificity, signaling pathways and kinetics of the TLR (Toll-like receptor) 9 suppression by inhibitory oligonucleotide motifs, which led to a class of novel inhibitory oligonucleotide (iODNs), that is independent of the previously thought species preference. Subsequently it has been discovered that telomeric DNA repeats (TTAGGG)n can block immune activation by CpG-ODNs. Short, 11-15 base long oligonucleotides were synthesized that were capable of potently inhibiting CpG-stimulation. The optimal inhibitory DNA motif consists of a pyrimidine-rich triplet, preferably CCT, which is positioned 5- to the GGG sequence in a singlestranded DNA molecule. Additionally, both the optimal spacing between the CCT and GGG motifs, as well as their relative order to each other, is of crucial importance for the inhibitory DNA action. Interestingly, although both TLR7/TLR8 ligands and bacterial DNA share the endosomal compartment for receptor binding and signal transduction, certain iODNs (G-type) suppress only TLR9-mediated activation, whereas prototype class I iODN may also interfere with the activation via the TLR7/TLR8 pathway. Recently, intriguing evidence has been presented that for some iODN classes the immuno-modulatory biological activity shows only limited sequence dependency or may not even involve TLR-mediated uptake and signaling pathways. For example iODNs of the class II are thought to act on immune activation through inhibition of STAT signaling and independent of TLR signaling via binding to a yet to be identified 'ODN-receptor'. Slightly modified phosphodiester versions of the most potent inhibitory ODNs were also able to profoundly block the immune activation of macrophages and just recently prove to be valuable tools for in vivo use in experimental animal models of inflammatory and auto-immune diseases. Based upon these recent insights the following classification for iODNs has been suggested:
Class I: G-stretch ODNs: TLR9-specific competitors, some iODNs may also affect TLR7 and TLR8 signaling
Class II: ODNs with telomeric repeats: TLR-independent inhibitors of STAT signaling (cellular uptake via an 'ODN receptor'?)
Class III: Inhibitors of DNA uptake in a sequence independent manner
Class IV: Long phosphorothioate ODNs as direct competitors of TLR9 signaling in a sequence independent manner
脂肪原
AdipoGen,Inc.通过免疫学知识和技术为基础的生物技术公司,公司的产品与肥胖症和II型糖尿病等代谢性疾病相关,包括替代的重组蛋白,抗体和ELISA试剂盒。主要研究方向:炎症,免疫(天然免疫,自然杀伤性T细胞(NKT细胞),T细胞生物学,感染),肿瘤研究(细胞死亡研究,药物抗性,生物标记物,血管新生),代谢(糖尿病,肥胖症,微量因子,动脉粥样硬化硬化性心血管疾病,线粒体功能障碍)。
Adipogen International试图以可承受的价格为客户提供最高质量的研究试剂。我们生产自己的试剂盒,抗体,蛋白质和小分子(生化试剂)。此外,我们通过与专家顾问,研究机构和学术实验室的密切合作来采购优质试剂。我们敬业的科研团队每天都会通过科学出版物进行搜索,并参加大型会议,以识别新思想和机遇并将其转化为创新和令人兴奋的研究试剂。我们专注于生命科学市场的特定领域。这些科学领域包括癌症,免疫学,炎症,代谢综合征(糖尿病,肥胖症),干细胞和神经变性。
如果您开发并生产了出色的试剂,或者您有有趣的产品构想,我们将很高兴与您讨论此类机会。也许我们可以营销和分销您的产品,或者我们可以合作开发新产品以使我们双方受益。
AdipoGen提供抗体,ELISA和生化试剂的服务。此外,我们还提供了一项新的“炎症活动测试”服务。您可以通过电子邮件与我们联系,以了解您的要求(请参见下面的相应电子邮件地址)。
定制抗体服务
•用以下分子标记多克隆和单克隆抗体: -ATTO荧光染料(不同波长)(488、590、647等) -FITC -生物素 -HRP•单克隆抗体的体外生产(在滚瓶或烧瓶中) •使用亲和色谱法纯化单克隆或多克隆抗体
•冻干
产品列表:
脂肪原 | AG-20A-0001-C050 | 抗脂联素(人类),单克隆抗体(HADI 773) | 50微克 |
脂肪原 | AG-20A-0001-C100 | 抗脂联素(人类),单克隆抗体(HADI 773) | 100微克 |
脂肪原 | AG-20A-0003-C050 | 抗脂联素(小鼠),单克隆抗体(MADI 1147) | 50微克 |
脂肪原 | AG-20A-0003-C100 | 抗脂联素(小鼠),单克隆抗体(MADI 1147) | 100微克 |
脂肪原 | AG-20A-0004-C050 | 抗抵抗素(小鼠),单克隆抗体(MRES 06) | 50微克 |
脂肪原 | AG-20A-0004-C100 | 抗抵抗素(小鼠),单克隆抗体(MRES 06) | 100微克 |
脂肪原 | AG-20A-0005-C050 | 抗脂联素(小鼠),单抗(MADI 04) | 50微克 |
脂肪原 | AG-20A-0005-C100 | 抗脂联素(小鼠),单抗(MADI 04) | 100微克 |
脂肪原 | AG-20A-0006-C050 | 抗脂联素(大鼠),单克隆抗体(RADI 06) | 50微克 |
脂肪原 | AG-20A-0006-C100 | 抗脂联素(大鼠),单克隆抗体(RADI 06) | 100微克 |
脂肪原 | AG-20A-0007-C050 | 抗GITR(小鼠),单克隆抗体(MGIT 02) | 50微克 |
脂肪原 | AG-20A-0007-C100 | 抗GITR(小鼠),单克隆抗体(MGIT 02) | 100微克 |
脂肪原 | AG-20A-0008-C050 | 抗GITR(小鼠),单克隆抗体(MGIT 07) | 50微克 |
脂肪原 | AG-20A-0008-C100 | 抗GITR(小鼠),单克隆抗体(MGIT 07) | 100微克 |
脂肪原 | AG-20A-0009-C050 | 抗GITRL(小鼠),单克隆抗体(MGTL 10) | 50微克 |
脂肪原 | AG-20A-0009-C100 | 抗GITRL(小鼠),单克隆抗体(MGTL 10) | 100微克 |
脂肪原 | AG-20A-0010-C050 | 抗GITRL(小鼠),单克隆抗体(MGTL 15) | 50微克 |
脂肪原 | AG-20A-0010-C100 | 抗GITRL(小鼠),单克隆抗体(MGTL 15) | 100微克 |
脂肪原 | AG-20A-0011-C050 | 抗瘦蛋白(人类),单克隆抗体(HLEP 55G) | 50微克 |
脂肪原 | AG-20A-0011-C100 | 抗瘦蛋白(人类),单克隆抗体(HLEP 55G) | 100微克 |
脂肪原 | AG-20A-0012-C050 | 抗RELM-beta(人类),单克隆抗体(HRB 149) | 50微克 |
脂肪原 | AG-20A-0012-C100 | 抗RELM-beta(人类),单克隆抗体(HRB 149) | 100微克 |
脂肪原 | AG-20A-0013-C050 | 抗RELM-beta(人类),单克隆抗体(HRB 46D) | 50微克 |
脂肪原 | AG-20A-0013-C100 | 抗RELM-beta(人类),单克隆抗体(HRB 46D) | 100微克 |
脂肪原 | AG-20A-0014-C050 | 抗抵抗素(大鼠),单克隆抗体(RRES 03) | 50微克 |
脂肪原 | AG-20A-0014-C100 | 抗抵抗素(大鼠),单克隆抗体(RRES 03) | 100微克 |
脂肪原 | AG-20A-0015-C050 | 抗抵抗素(大鼠),单克隆抗体(RRES 07) | 50微克 |
脂肪原 | AG-20A-0015-C100 | 抗抵抗素(大鼠),单克隆抗体(RRES 07) | 100微克 |
脂肪原 | AG-20A-0016-C050 | 抗SHP(人类),单克隆抗体(SH2G5-C) | 50微克 |
脂肪原 | AG-20A-0016-C100 | 抗SHP(人类),单克隆抗体(SH2G5-C) | 100微克 |
脂肪原 | AG-20A-0017-C050 | 抗GITR(人类),单克隆抗体(AIT 158D) | 50微克 |
脂肪原 | AG-20A-0017-C100 | 抗GITR(人类),单克隆抗体(AIT 158D) | 100微克 |
脂肪原 | AG-20A-0018-C050 | 抗瘦素(大鼠),单克隆抗体(RLEP 227) | 50微克 |
脂肪原 | AG-20A-0018-C100 | 抗瘦素(大鼠),单克隆抗体(RLEP 227) | 100微克 |
脂肪原 | AG-20A-0019-C050 | 抗瘦蛋白(人类),单克隆抗体(HLEP 155) | 50微克 |
脂肪原 | AG-20A-0019-C100 | 抗瘦蛋白(人类),单克隆抗体(HLEP 155) | 100微克 |
脂肪原 | AG-20A-0020-C050 | 抗RELM-alpha(小鼠),单抗(MREL 384) | 50微克 |
脂肪原 | AG-20A-0020-C100 | 抗RELM-alpha(小鼠),单抗(MREL 384) | 100微克 |
脂肪原 | AG-20A-0021-C050 | 抗RELM-alpha(大鼠),单克隆抗体(RREL 804) | 50微克 |
脂肪原 | AG-20A-0021-C100 | 抗RELM-alpha(大鼠),单克隆抗体(RREL 804) | 100微克 |
脂肪原 | AG-20A-0022-C050 | 抗单核细胞增生李斯特菌p60,mAb(P6007) | 50微克 |